# Javier Cortés

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/javier-cortes/

## Facts

| Field | Value |
| --- | --- |
| Citations | 71,872 |
| Field | Advanced Breast Cancer Therapies |
| h-index | 115 |
| i10-index | 514 |
| Last Known Institution | Villa Maria Hospital |
| OpenAlex ID | https://openalex.org/A5051629490 |
| ORCID iD | https://orcid.org/0000-0001-7623-1583 |
| Works | 1,475 |

## Researcher papers

Showing 12 of 16.

- [Pembrolizumab for Early Triple-Negative Breast Cancer](https://scholariq.org/papers/pembrolizumab-for-early-triple-negative-breast-cancer/)
- [Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer](https://scholariq.org/papers/sacituzumab-govitecan-in-metastatic-triple-negative-breast-cancer/)
- [ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer](https://scholariq.org/papers/esmo-clinical-practice-guideline-for-the-diagnosis-staging-and-treatment-of/)
- [5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)](https://scholariq.org/papers/5th-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-5/)
- [4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)](https://scholariq.org/papers/4th-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-4/)
- [Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/pertuzumab-trastuzumab-and-docetaxel-for-her2-positive-metastatic-breast-cancer/)
- [Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study](https://scholariq.org/papers/pembrolizumab-monotherapy-for-previously-treated-metastatic-triple-negative/)
- [Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial](https://scholariq.org/papers/elacestrant-oral-selective-estrogen-receptor-degrader-versus-standard-endocrine/)
- [MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer](https://scholariq.org/papers/monarch-1-a-phase-ii-study-of-abemaciclib-a-cdk4-and-cdk6-inhibitor-as-a-single/)
- [Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/pembrolizumab-versus-investigator-choice-chemotherapy-for-metastatic-triple/)
- [A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds](https://scholariq.org/papers/a-biobank-of-breast-cancer-explants-with-preserved-intra-tumor-heterogeneity-to/)
- [PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer](https://scholariq.org/papers/pi3k-inhibition-results-in-enhanced-estrogen-receptor-function-and-dependence-in/)

## Researcher topics

- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [Villa Maria Hospital](https://scholariq.org/institutions/villa-maria-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.